查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
生物感應器市場:藥物研發與開發 - 各生物感應器類型，各終端用戶類型，各主要地區，產業趨勢與全球市場預測(2022年～2035年)
市場調查報告書
商品編碼
1101053

生物感應器市場:藥物研發與開發 - 各生物感應器類型，各終端用戶類型，各主要地區，產業趨勢與全球市場預測(2022年～2035年)

Biosensors Market: Focus on Drug Discovery and Development - Distribution by Type of Biosensor, Type of End User and Key Geographies - Industry Trends and Global Forecasts, 2022-2035
出版日期: | 出版商: Roots Analysis | 英文 217 Pages | 商品交期: 最快1-2個工作天內

價格

本報告提供全球生物感應器市場相關調查，市場概要，以及各生物感應器類型，各終端用戶類型，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 簡介

  • 章概要
  • 生物感應器概要
  • 生物感應器的結構要素
  • 生物感應器的種類
  • 開發藥劑中生物感應器的應用
  • 開發藥劑中生物感應器的使用相關的課題
  • 結束

第4章 市場形勢

  • 章概要
  • 開發藥劑中生物感應器:整體市場形勢

第5章 產品的競爭力分析

  • 章概要
  • 假設主要的參數
  • 調查手法
  • 產品的競爭力分析:開發藥劑中生物感應器

第6章 企業簡介概要:藥物研發的生物感應器開發業者

  • 章概要
  • Agilent Technologies
  • Axion Biosystems
  • BioNavigations
  • Creoptix
  • Cytiva
  • Dynamic Biosensors
  • Malvern Panalytical
  • Microvacuum
  • Sartorius
  • Tempo Bioscience

第7章 品牌定位分析

  • 章概要
  • 主要的參數
  • 調查手法
  • 藥物研發用的生物感應器開發業者

第8章 資金籌措投資分析

  • 章概要
  • 資金的種類
  • 開發藥劑中生物感應器:資金籌措與投資

第9章 出版物的分析

第10章 世界活動分析

  • 章概要
  • 範圍與調查手法
  • 開發藥劑中生物感應器相關的世界活動的清單

第11章 專利分析

第12章 市場預測機會分析

  • 章概要
  • 預測調查手法主要的假設
  • 藥物研發市場上世界生物感應器，從2022年到2035年
    • 藥物研發市場上生物感應器:生物感應器類型，2022年及2035年
    • 藥物研發市場上生物感應器:各終端用戶類型，2022年及2035年
    • 藥物研發市場上生物感應器:各地區，2022年及2035年

第13章 結論

第14章 執行見解

第15章 附錄1:總計資料

第16章 附錄2:企業和組織的清單

Product Code: RA100362

INTRODUCTION

The drug discovery process, which involves the identification of a relevant biological target and a corresponding pharmacological lead, is deemed crucial to the clinical success of a drug candidate. However, considering the growing complexity of modern pharmacology, the discovery of viable therapeutic candidates is very demanding, both in terms of time and capital investment. In fact, as per estimates, a therapeutic drug takes around 10 to 15 years and an average investment of USD 1 to 2 billion, to traverse from the bench to the market. It is also a well-known fact that only a small proportion of pharmacological leads, identified during the discovery stages, are actually translated into viable product candidates for clinical studies. Experts believe that close to 90% of the product candidates fail to make it past the clinical stage of development. The high attrition rate has long been attributed to the legacy drug discovery process, which is more of a trial-and-error paradigm. In attempts to address the concerns associated with rising capital requirements in drug discovery and prevent late stage failure of drug development programs, stakeholders in the pharmaceutical industry are currently exploring the implementation of biosensors (an analytical device consisting of a biological component, such as antibodies, enzymes, cells, lipids and oligonucleotides, and a physical transducer) to enable the effective screening of lead drug candidates from thousands of hits. Further, biosensors can be used for routine analysis of known, as well as unknown, analytes.

At present, various types of biosensors, including optical biosensors, electrochemical biosensors, thermal biosensors and others, are being deployed across different steps of drug discovery, such as disease modelling, target identification / validation, lead identification, lead optimization and other applications. It is worth mentioning that the use of biosensing technologies in drug discovery operations is expected to improve the overall R&D productivity by enabling accurate screening and identification of lead drug compounds. Currently, more than 80 biosensors are available in the market / being developed by various industry stakeholders for drug discovery and development purposes. Further, over USD 1.2 billion has been invested in this market by both private and public sector investors, in the last five years. Interestingly, close to 50% of the aforementioned amount was invested in the last two years, reflecting the increasing interest of stakeholders in this domain. It is also worth highlighting that over 370 patents related to biosensors in drug discovery have been filed / granted, highlighting the continuous pace of innovation in this field. Considering the active initiatives being undertaken by players in this domain, we are led to believe that the opportunity for stakeholders in this niche, but upcoming, industry is likely to grow at a commendable pace in the foreseen future.

SCOPE OF THE REPORT

The "Biosensors Market: Focus on Drug Discovery and Development - Distribution by Type of Biosensor (Optical, Electrochemical, Thermal and Others), Type of End User (Academic and Research Institutes and Industry Players) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current market landscape and future potential of biosensors in drug discovery, over the next 13 years. The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of biosensors in drug discovery, along with information on several relevant parameters, such as type of biosensor (optical biosensors, electrochemical biosensors, quartz crystal microbalance biosensors, thermal biosensors and magneto-electric biosensors), bioreceptor used (cells, proteins, lipids, enzymes, antibodies and undisclosed), drug discovery step(s) supported (disease modelling, target identification / validation, lead identification, lead optimization, and drug discovery (unspecified)), other applications (ADME assays, toxicity assays, cytotoxicity assays, cell analysis, drug characterization / validation assays and other assays), type of analyte analyzed (small molecules, cell / tissues, protein / peptides, antibodies, nucleotides, viruses, blood products, enzymes, biologics (unspecified) and others), type of carrier plate format (microplate-based sensor, flow through the sensor, chip-based static array sensor, polymerase chain reaction (PCR) format plates-based sensor and undisclosed), sample capacity (less than 96, 96 to 384, 385 to 1536, more than 1536 and undisclosed), sample volume (1 to 50µl, 51 to 100 µl, 101 to 200 µl, more than 200 µl and undisclosed), type of detection (label-free and real-time) and type of system (automatic, semi-automatic and undisclosed). In addition, the chapter features analysis related to biosensor developers based on multiple parameters, such as their year of establishment, company size, location of headquarters and leading players (in terms of number of biosensors developed).
  • A product competitiveness analysis of biosensors used for drug discovery purposes based on various relevant parameters, namely supplier power (in terms of the experience of the developer) and product competitiveness (in terms of type of biosensor, bioreceptor used, drug discovery step(s) supported, other application(s), type of analyte(s) analyzed, type of carrier plate, sample capacity, type of detection, and type of system used).
  • Elaborate profiles of prominent players developing biosensors for drug discovery applications. Each profile features a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.
  • An elaborate brand positioning analysis of leading industry players (shortlisted on the basis of year of establishment, number of biosensors developed and company size), highlighting the current perceptions regarding their proprietary brands, across biosensors in drug discovery.
  • An analysis of investments that have been made into companies developing biosensors for drug discovery applications, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.
  • A detailed review of over 333 peer-reviewed, scientific articles related to research on biosensors in drug discovery on the basis of several relevant parameters, such as year of publication, type of publication, emerging focus areas, most active publishers, most active affiliated institutes and geography. The chapter also highlights the top journals, in terms of number of articles published and impact factor.
  • A detailed analysis of the global events attended by participants, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, and affiliated organizations of participant. The chapter also highlights the geographical mapping of upcoming events.
  • An in-depth analysis of various patents that have been filed / granted related to biosensors in drug discovery, during the period 2018-2022, taking into consideration parameters, such as publication year, geographical region, CPC symbols, patent focus areas, type of applicant, detailed valuation analysis and leading players (in terms of size of intellectual property portfolio).

One of the key objectives of the report was to evaluate the current opportunity and future potential associated with biosensors in drug discovery, over the coming 13 years. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as [A] type of biosensor (optical, electrochemical, thermal and others), [B] type of end user (academic and research institutes, and industry players) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Bill Rader (Chief Executive Officer, Efferent Labs),
  • Anne Marie Quinn (Chief Executive Officer, Montana Molecular)
  • Laurent Sabbagh (Associate Director R&D and Head of Biology, Domain Therapeutics)

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in this domain (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED

  • Who are the key players engaged in the biosensors in drug discovery market?
  • What is the relative competitiveness of different biosensors being developed for drug discovery applications?
  • What are the key agenda items being discussed in various global events / conferences related to biosensors in drug discovery?
  • What is the focus area of the ongoing research activity related to biosensors in drug discovery?
  • How is the intellectual property landscape for biosensors in drug discovery likely to evolve in the foreseen future?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

CHAPTER OUTLINES

  • Chapter 2 is an executive summary of the key insights captured in our report. It offers a high-level view of the current state of biosensors in drug discovery market and its likely evolution in the short term, mid-term and long term.
  • Chapter 3 provides a general overview of biosensors and its different components, including analyte, bioreceptor, transducer, electronics and display. Additionally, it highlights different types of biosensors, along with their applications in drug discovery. Further, the chapter includes information on the challenges associated with use of biosensors in this domain.
  • Chapter 4 provides a detailed review of the current market landscape of biosensors in drug discovery, featuring information on the type of biosensor (optical biosensors, electrochemical biosensors, quartz crystal microbalance biosensors, thermal biosensors and magneto-electric biosensors), bioreceptor used (cells, proteins, lipids, enzymes, antibodies and undisclosed), drug discovery step(s) supported (disease modelling, target identification / validation, lead identification, lead optimization, and drug discovery (unspecified)), other applications (ADME assays, toxicity assays, cytotoxicity assays, cell analysis, drug characterization / validation assays and other assays), type of analyte analyzed (small molecules, cell / tissues, protein / peptides, antibodies, nucleotides, viruses, blood products, enzymes, biologics (unspecified) and others), type of carrier plate format (microplate-based sensor, flow through the sensor, chip-based static array sensor, polymerase chain reaction (PCR) format plates-based sensor and undisclosed), sample capacity (less than 96, 96 to 384, 385 to 1536, more than 1,536 and undisclosed), sample volume (1 to 50µl, 51 to 100 µl, 101 to 200 µl, more than 200 µl and undisclosed), type of detection (label-free and real-time) and type of systems (automatic, semi-automatic and undisclosed). In addition, the chapter features analysis related to biosensor developers based on multiple parameters, such as their year of establishment, company size, location of headquarters and leading players (in terms of number of biosensors developed).
  • Chapter 5 presents a detailed product competitiveness analysis of biosensors in drug discovery, based on various relevant parameters, namely supplier power (based on the experience of the developer) and product competitiveness (based on various parameters, including type of biosensor, bioreceptor used, drug discovery step(s) supported, other application(s), type of analyte(s) analyzed, type of carrier plate, sample capacity, type of detection, and type of system used).
  • Chapter 6 features detailed profiles of the prominent players offering biosensors for drug discovery applications. Each profile features a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.
  • Chapter 7 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment, number of biosensors developed and company size), highlighting the current perceptions regarding their proprietary brands across biosensors in drug discovery.
  • Chapter 8 provides details on the various investments that have been made into companies developing biosensors for drug discovery applications, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances and amount) and type of investor.
  • Chapter 9 features a detailed review of peer-reviewed, scientific articles related to research on biosensors in drug discovery, on the basis of several relevant parameters, such as year of publication, type of publication, emerging focus areas, most active publisher, most active affiliated institutes and geography. The chapter also highlights the top journals (in terms of number of articles published and impact factor).
  • Chapter 10 features an analysis of the global events attended by the participants, based on several parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated organizations of participant. The chapter also highlights the geographical mapping of upcoming events.
  • Chapter 11 provides an insightful analysis of the patents filed / granted for biosensors used for drug discovery during the period between 2018 and 2022 taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus area, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.
  • Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the biosensors in drug discovery market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of biosensor (optical, electrochemical, thermal and others), [B] type of end user (academic and research institutes, and industry players) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world).
  • Chapter 13 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
  • Chapter 14 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Bill Rader (Chief Executive Officer, Efferent Labs), Anne Marie Quinn (Chief Executive Officer, Montana Molecular), and Laurent Sabbagh (Associate Director R&D and Head of Biology, Domain Therapeutics).
  • Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
  • Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. An Overview of Biosensors
  • 3.3. Components of Biosensors
  • 3.4. Types of Biosensors
  • 3.5. Applications of Biosensors in Drug Discovery
  • 3.6. Challenges Associated with Use of Biosensors in Drug Discovery
  • 3.7. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Biosensors in Drug Discovery: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Most Active Players: Analysis by Number of Biosensors Developed
    • 4.2.5. Analysis by Type of Biosensor
    • 4.2.6. Analysis by Type of Bioreceptor Used
    • 4.2.7. Analysis by Type of Biosensor and Type of Bioreceptor Used
    • 4.2.8. Analysis by Drug Discovery Step(s) Supported
    • 4.2.9. Analysis by Other Applications Supported
    • 4.2.10. Analysis by Type of Analyte
    • 4.2.11. Analysis by Carrier Plate Format
    • 4.2.12. Analysis by Type of Biosensor and Carrier Plate Format
    • 4.2.13. Analysis by Sample Capacity
    • 4.2.14. Analysis by Sample Volume
    • 4.2.15. Analysis by Type of Detection Method Employed
    • 4.2.16. Analysis by Type of System

5. PRODUCT COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Key Parameters
  • 5.3. Methodology
  • 5.3. Product Competitiveness Analysis: Biosensors in Drug Discovery

6. COMPANY PROFILES: BIOSENSORS DEVELOPERS FOR DRUG DISCOVERY APPLICATIONS

  • 6.1. Chapter Overview
  • 6.2. Agilent Technologies
    • 6.2.1. Company Overview
    • 6.2.2. Product Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. Axion Biosystems
    • 6.3.1. Company Overview
    • 6.3.2. Product Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. BioNavigations
    • 6.4.1. Company Overview
    • 6.4.2. Product Portfolio
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. Creoptix
    • 6.5.1. Company Overview
    • 6.5.2. Product Portfolio
    • 6.5.3. Recent Developments and Future Outlook
  • 6.6. Cytiva
    • 6.6.1. Company Overview
    • 6.6.2. Product Portfolio
    • 6.6.3. Recent Developments and Future Outlook
  • 6.7. Dynamic Biosensors
    • 6.7.1. Company Overview
    • 6.7.2. Product Portfolio
    • 6.7.3. Recent Developments and Future Outlook
  • 6.8. Malvern Panalytical
    • 6.8.1. Company Overview
    • 6.8.2. Product Portfolio
    • 6.8.3. Recent Developments and Future Outlook
  • 6.9. Microvacuum
    • 6.9.1. Company Overview
    • 6.9.2. Product Portfolio
    • 6.9.3. Recent Developments and Future Outlook
  • 6.10. Sartorius
    • 6.10.1. Company Overview
    • 6.10.2. Product Portfolio
    • 6.10.3. Recent Developments and Future Outlook
  • 6.11. Tempo Bioscience
    • 6.11.1. Company Overview
    • 6.11.2. Product Portfolio
    • 6.11.3. Recent Developments and Future Outlook

7. BRAND POSITIONING ANALYSIS

  • 7.1. Chapter Overview
  • 7.2 Key Parameters
  • 7.3. Methodology
  • 7.4. Biosensor Developers for Drug Discovery Applications
    • 7.4.1. Brand Positioning Matrix: Agilent Technologies
    • 7.4.2. Brand Positioning Matrix: Cytiva
    • 7.4.3. Brand Positioning Matrix: Sartorius
    • 7.4.4. Brand Positioning Matrix: Malvern Panalytical

8. FUNDING AND INVESTMENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Types of Funding
  • 8.3. Biosensors in Drug Discovery: Funding and Investments
    • 8.3.1. Analysis of Funding Instances by Year
    • 8.3.2. Analysis of Amount Invested by Year
    • 8.3.3. Analysis of Funding Instances by Type of Funding
    • 8.3.4. Analysis of Amount Invested by Type of Funding
    • 8.3.5. Analysis of Funding Instances by Type of Biosensor
    • 8.3.6. Most Active Players: Analysis by Number of Funding Instances
    • 8.3.7. Most Active Players: Analysis by Amount Invested
    • 8.3.8. Most Active Investors: Analysis by Number of Funding Instances
    • 8.3.9. Analysis of Amount Invested by Geography
      • 8.3.9.1. Analysis by Region
      • 8.3.9.2. Analysis by Country

9. PUBLICATION ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Biosensors in Drug Discovery: Publication Analysis
    • 9.3.1. Analysis by Year of Publication
    • 9.3.2. Analysis by Type of Publication
    • 9.3.3. Most Popular Journals: Analysis by Number of Publications
    • 9.3.4. Most Popular Journals: Analysis by Impact Factor
    • 9.3.5. Analysis by Most Popular Keywords
    • 9.3.6. Most Active Publisher: Analysis by Number of Publications
    • 9.3.7. Most Active Affiliated Institutes: Analysis by Number of Publications
    • 9.3.8. Analysis by Geography

10. GLOBAL EVENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. List of Global Events Related to Biosensors in Drug Discovery
    • 10.3.1. Analysis by Year of Event
    • 10.3.2. Analysis by Event Platform
    • 10.3.3. Analysis by Type of Event
    • 10.3.4. Analysis by Location of Event
    • 10.3.5. Analysis by Evolutionary Trends in Event Agendas / Key Focus Areas
    • 10.3.6. Most Active Organizers: Analysis by Number of Events
    • 10.3.7. Analysis by Designation of Participants
    • 10.3.8. Analysis by Affiliated Department of Participants
    • 10.3.9. Analysis by Geography of Upcoming Events

11. PATENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Biosensors in Drug Discovery: Patent Analysis
    • 11.3.1. Analysis by Publication Year
    • 11.3.2. Analysis by Geography
    • 11.3.3. Analysis by CPC Symbols
    • 11.3.4. Analysis by Emerging Focus Areas
    • 11.3.5. Analysis by Patent Age
    • 11.3.6. Analysis by Type of Applicant
    • 11.3.7. Leading Industry Players: Analysis by Number of Patents
    • 11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 11.3.9. Leading Individual Assignees: Analysis by Number of Patents
  • 11.4. Biosensors in Drug Discovery: Patent Valuation
  • 11.5. Leading Patents: Analysis by Number of Citations

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Global Biosensors in Drug Discovery Market, 2022-2035
    • 12.3.1. Biosensors in Drug Discovery Market: Distribution by Type of Biosensor, 2022 and 2035
      • 12.3.1.1. Optical Biosensors in Drug Discovery Market, 2022-2035
      • 12.3.1.2. Electrochemical Biosensors in Drug Discovery Market, 2022-2035
      • 12.3.1.3. Thermal Biosensors in Drug Discovery Market, 2022-2035
      • 12.3.1.4. Other Biosensors in Drug Discovery Market, 2022-2035
    • 12.3.2. Biosensor in Drug Discovery Market: Distribution by Type of End User, 2022 and 2035
      • 12.3.2.1. Biosensor in Drug Discovery Market for Academic and Research Institutes, 2022-2035
      • 12.3.2.2. Biosensor in Drug Discovery Market for Industry Players, 2022-2035
    • 12.3.3. Biosensor in Drug Discovery Market: Distribution by Region, 2022 and 2035
      • 12.3.3.1. Biosensor in Drug Discovery Market in North America, 2022-2035
      • 13.3.3.2. Biosensor in Drug Discovery Market in Europe, 2022-2035
      • 12.3.3.3. Biosensor in Drug Discovery Market in Asia Pacific, 2022-2035
      • 12.3.3.4. Biosensor in Drug Discovery Market in Latin America, 2022-2035
      • 12.3.3.5. Biosensor in Drug Discovery Market in Middle East and North Africa, 2022-2035
      • 12.3.3.6. Biosensor in Drug Discovery Market in Rest of the World, 2022-2035

13. CONCLUDING REMARKS

14. EXECUTIVE INSIGHTS

  • 14.1. Chapter Overview
  • 14.2. Efferent Labs
    • 14.2.1. Company Snapshot
    • 14.2.2. Interview Transcript: Bill Rader (Chief Executive Officer)
  • 14.3. Montana Molecular
    • 14.3.1. Company Snapshot
    • 14.3.2. Interview Transcript: Anne Marie Quinn (Chief Executive Officer)
  • 14.4. Domain Therapeutics
    • 14.4.1. Company Snapshot
    • 14.4.2. Interview Transcript: Laurent Sabbagh (Associate Director R&D, Head of

Biology)

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

  • Table 4.1 Biosensors in Drug Discovery: List of Companies
  • Table 4.2 Biosensors in Drug Discovery: Information on Type of Biosensor, Bioreceptor used, Drug Discovery Step(s) and Other Applications Supported
  • Table 4.3 Biosensors in Drug Discovery: Information on Type of Analyte
  • Table 4.4 Biosensors in Drug Discovery: Information on Carrier Plate Format, Sample Capacity, Sample Volume, Type of Detection Method Employed and Type of System
  • Table 6.1 Leading Biosensor Developers
  • Table 6.2 Agilent Technologies: Company Overview
  • Table 6.3 Agilent Technologies: Product Portfolio
  • Table 6.4 Agilent Technologies: Recent Developments and Future Outlook
  • Table 6.5 Axion Biosystems: Company Overview
  • Table 6.6 Axion Biosystems: Product Portfolio
  • Table 6.7 BioNavigations: Company Overview
  • Table 6.8 BioNavigations: Product Portfolio
  • Table 6.9 Creoptix: Company Overview
  • Table 6.10 Creoptix: Product Portfolio
  • Table 6.11 Creoptix: Recent Developments and Future Outlook
  • Table 6.12 Cytiva: Company Overview
  • Table 6.13 Cytiva: Product Portfolio
  • Table 6.14 Cytiva: Recent Developments and Future Outlook
  • Table 6.15 Dynamic Biosensors: Company Overview
  • Table 6.16 Dynamic Biosensors: Product Portfolio
  • Table 6.17 Dynamic Biosensors: Recent Developments and Future Outlook
  • Table 6.18 Malvern Panalytical: Company Overview
  • Table 6.19 Malvern Panalytical: Product Portfolio
  • Table 6.20 Malvern Panalytical: Recent Developments and Future Outlook
  • Table 6.21 Microvacuum: Company Overview
  • Table 6.22 Microvacuum: Product Portfolio
  • Table 6.23 Sartorius: Company Overview
  • Table 6.24 Sartorius: Product Portfolio
  • Table 6.25 Sartorius: Recent Developments and Future Outlook
  • Table 6.26 Tempo Bioscience: Company Overview
  • Table 6.27 Tempo Bioscience: Product Portfolio
  • Table 8.1 Biosensors in Drug Discovery: List of Funding and Investments, 2018-2022
  • Table 9.1 Biosensors in Drug Discovery: List of Recent Publications, 2018-2022
  • Table 10.1 Biosensors in Drug Discovery: List of Global Events, 2021-H2 2023
  • Table 11.1 Patent Analysis: Prominent CPC Symbols
  • Table 11.2 Patent Analysis: Most Popular CPC Symbols
  • Table 11.3 Patent Analysis: List of Top CPC Symbols
  • Table 11.4 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 11.5 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
  • Table 11.6 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
  • Table 14.1 Efferent Labs: Company Snapshot
  • Table 14.2 Montana Molecular: Company Snapshot
  • Table 14.2 Domain Therapeutics: Company Snapshot
  • Table 15.1 Biosensor Developers for Drug Discovery Applications: Distribution by Year of Establishment
  • Table 15.2 Biosensor Developers for Drug Discovery Applications: Distribution by Company Size
  • Table 15.3 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters (Region-wise)
  • Table 15.4 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters (Country-wise)
  • Table 15.5 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters and Company Size
  • Table 15.6 Most Active Players: Distribution by Number of Biosensors Developed
  • Table 15.7 Biosensors in Drug Discovery: Distribution by Type of Biosensor
  • Table 15.8 Biosensors in Drug Discovery: Distribution by Type of Bioreceptor Used
  • Table 15.9 Biosensors in Drug Discovery: Distribution by Type of Biosensor and Type of Bioreceptor Used
  • Table 15.10 Biosensors in Drug Discovery: Distribution by Drug Discovery Step(s) Supported
  • Table 15.11 Biosensors in Drug Discovery: Distribution by Other Applications Supported
  • Table 15.12 Biosensors in Drug Discovery: Distribution by Type of Analyte
  • Table 15.13 Biosensors in Drug Discovery: Distribution by Carrier Plate Format
  • Table 15.14 Biosensors in Drug Discovery: Distribution by Type of Biosensor and Carrier Plate Format
  • Table 15.15 Biosensors in Drug Discovery: Distribution by Sample Capacity
  • Table 15.16 Biosensors in Drug Discovery: Distribution by Sample Volume
  • Table 15.17 Biosensors in Drug Discovery: Distribution by Type of Detection Method Employed
  • Table 15.18 Biosensors in Drug Discovery: Distribution by Type of System
  • Table 15.19 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2018-2022
  • Table 15.20 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2018-2022 (USD Million)
  • Table 15.21 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
  • Table 15.22 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 15.23 Funding and Investment Analysis: Distribution of Funding Instances by Type of Biosensor
  • Table 15.24 Most Active Players: Distribution by Number of Funding Instances
  • Table 15.25 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 15.26 Most Active Investors: Distribution by Number of Funding Instances
  • Table 15.27 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
  • Table 15.28 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
  • Table 15.29 Publication Analysis: Distribution by Year of Publication
  • Table 15.30 Publication Analysis: Distribution by Type of Publication
  • Table 15.31 Most Popular Journals: Distribution by Number of Publications
  • Table 15.32 Most Popular Journals: Distribution by Impact Factor
  • Table 15.33 Publication Analysis: Most Popular Keywords
  • Table 15.34 Most Active Publisher: Distribution by Number of Publications
  • Table 15.35 Most Active Affiliated Institutes: Distribution by Number of Publications
  • Table 15.36 Publication Analysis: Distribution by Geography
  • Table 15.37 Global Event Analysis: Cumulative Quarterly Trend
  • Table 15.38 Global Event Analysis: Distribution by Event Platform
  • Table 15.39 Global Event Analysis: Distribution by Type of Event
  • Table 15.40 Global Event Analysis: Distribution by Location of Event
  • Table 15.41 Most Active Organizers: Distribution by Number of Events
  • Table 15.42 Global Event Analysis: Distribution by Designation of Participants
  • Table 15.43 Global Event Analysis: Distribution by Affiliated Department of Participants
  • Table 15.44 Global Event Analysis: Geographical Mapping of Upcoming Events
  • Table 15.45 Patent Analysis: Distribution by Type of Patent
  • Table 15.46 Patent Analysis: Distribution by Patent Publication Year
  • Table 15.47 Patent Analysis: Distribution by Geography
  • Table 15.48 Patent Analysis: Distribution by CPC Symbols
  • Table 15.49 Patent Analysis: Distribution by Patents Age
  • Table 15.50 Patent Analysis: Distribution by Type of Applicant
  • Table 15.51 Leading Industry Players: Distribution by Number of Patents
  • Table 15.52 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 15.53 Leading Individual Assignees: Distribution by Number of Patents
  • Table 15.54 Biosensors in Drug Discovery: Patent Valuation Analysis
  • Table 15.55 Global Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.56 Biosensors in Drug Discovery Market: Distribution by Type of Biosensor, 2022 and 2035
  • Table 15.57 Optical Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.58 Electrochemical Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.59 Thermal Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.60 Other Biosensors in Drug Discovery Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.61 Biosensors in Drug Discovery Market: Distribution by Type of End User, 2022 and 2035
  • Table 15.62 Biosensors in Drug Discovery Market for Academic and Research Institutions, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.63 Biosensors in Drug Discovery Market for Industry Players, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.64 Biosensors in Drug Discovery Market: Distribution by Region, 2022 and 2035
  • Table 15.65 Biosensors in Drug Discovery Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.66 Biosensors in Drug Discovery Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.67 Biosensors in Drug Discovery Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.68 Biosensors in Drug Discovery Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.69 Biosensors in Drug Discovery Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 15.70 Biosensors in Drug Discovery Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Funding and Investments
  • Figure 2.3 Executive Summary: Publication Analysis
  • Figure 2.4 Executive Summary: Global Event Analysis
  • Figure 2.5 Executive Summary: Patent Analysis
  • Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Components of Biosensors
  • Figure 3.2 Electrochemical Biosensor
  • Figure 3.3 Thermal Biosensor
  • Figure 3.4 Optical Biosensor
  • Figure 3.5 Piezo-electric Biosensor
  • Figure 3.4 Resonant Biosensor
  • Figure 4.1 Biosensor Developers for Drug Discovery Applications: Distribution by Year of Establishment
  • Figure 4.2 Biosensor Developers for Drug Discovery Applications: Distribution by Company Size
  • Figure 4.3 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.4 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.5 Biosensor Developers for Drug Discovery Applications: Distribution by Location of Headquarters and Company Size
  • Figure 4.6 Most Active Players: Distribution by Number of Biosensors Developed
  • Figure 4.7 Biosensors in Drug Discovery: Distribution by Type of Biosensor
  • Figure 4.8 Biosensors in Drug Discovery: Distribution by Type of Bioreceptor Used
  • Figure 4.9 Biosensors in Drug Discovery: Distribution by Type of Biosensor and Type of Bioreceptor Used
  • Figure 4.10 Biosensors in Drug Discovery: Distribution by Drug Discovery Step(s) Supported
  • Figure 4.11 Biosensors in Drug Discovery: Distribution by Other Applications Supported
  • Figure 4.12 Biosensors in Drug Discovery: Distribution by Type of Analyte
  • Figure 4.13 Biosensors in Drug Discovery: Distribution by Carrier Plate Format
  • Figure 4.14 Biosensors in Drug Discovery: Distribution by Type of Biosensor and Carrier Plate Format
  • Figure 4.15 Biosensors in Drug Discovery: Distribution by Sample Capacity
  • Figure 4.16 Biosensors in Drug Discovery: Distribution by Sample Volume
  • Figure 4.17 Biosensors in Drug Discovery: Distribution by Type of Detection Method Employed
  • Figure 4.18 Biosensors in Drug Discovery: Distribution by Type of System
  • Figure 5.1 Product Competitiveness Analysis: Dot Plot Analysis
  • Figure 5.2 Product Competitiveness Analysis: Biosensors in Drug Discovery
  • Figure 7.1 Biosensor Developers for Drug Discovery Applications: Brand Positioning Matrix
  • Figure 7.2 Brand Positioning Matrix: Agilent Technologies
  • Figure 7.3 Brand Positioning Matrix: Cytiva
  • Figure 7.4 Brand Positioning Matrix: Sartorius
  • Figure 7.5 Brand Positioning Matrix: Malvern Panalytical
  • Figure 8.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2018-2022
  • Figure 8.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2018-2022 (USD Million)
  • Figure 8.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
  • Figure 8.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 8.5 Funding and Investment Analysis: Distribution of Funding Instances by Type of Biosensor
  • Figure 8.6 Most Active Players: Distribution by Number of Funding Instances
  • Figure 8.7 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 8.8 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 8.9 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
  • Figure 8.10 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
  • Figure 9.1 Publication Analysis: Distribution by Year of Publication
  • Figure 9.2 Publication Analysis: Distribution by Type of Publication
  • Figure 9.3 Most Popular Journals: Distribution by Number of Publications
  • Figure 9.4 Most Popular Journals: Distribution by Impact Factor
  • Figure 9.5 Publication Analysis: Most Popular Keywords
  • Figure 9.6 Most Active Publisher: Distribution by Number of Publications
  • Figure 9.7 Most Active Affiliated Institutes: Distribution by Number of Publications
  • Figure 9.8 Publication Analysis: Distribution by Geography
  • Figure 10.1 Global Event Analysis: Cumulative Quarterly Trend
  • Figure 10.2 Global Event Analysis: Distribution by Event Platform
  • Figure 10.3 Global Event Analysis: Distribution by Type of Event
  • Figure 10.4 Global Event Analysis: Distribution by Location of Event
  • Figure 10.5 Global Event Analysis: Distribution by Evolutionary Trends in Event Agenda / Key Focus Area
  • Figure 10.6 Most Active Organizers: Distribution by Number of Events
  • Figure 10.7 Global Event Analysis: Distribution by Designation of Participants
  • Figure 10.8 Global Event Analysis: Distribution by Affiliated Department of Participants
  • Figure 10.9 Global Event Analysis: Geography of Upcoming Events
  • Figure 11.1 Patent Analysis: Distribution by Type of Patent
  • Figure 11.2 Patent Analysis: Distribution by Patent Publication Year
  • Figure 11.3 Patent Analysis: Distribution by Geography
  • Figure 11.4 Patent Analysis: Distribution by CPC Symbols
  • Figure 11.5 Patent Analysis: Emerging Focus Areas
  • Figure 11.6 Patent Analysis: Distribution by Patents Age
  • Figure 11.7 Patent Analysis: Distribution by Type of Applicant
  • Figure 11.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 11.10 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 11.11 Biosensors in Drug Discovery: Patent Valuation Analysis
  • Figure 12.1 Global Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
  • Figure 12.2 Biosensors in Drug Discovery Market: Likely Growth Scenarios
  • Figure 12.3 Biosensors in Drug Discovery Market: Distribution by Type of Biosensor, 2022 and 2035 (USD Billion)
  • Figure 12.4 Optical Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
  • Figure 12.5 Electrochemical Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
  • Figure 12.6 Thermal Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
  • Figure 12.7 Other Biosensors in Drug Discovery Market, 2022-2035 (USD Billion)
  • Figure 12.8 Biosensors in Drug Discovery Market: Distribution by Type of End User, 2022 and 2035
  • Figure 12.9 Biosensors in Drug Discovery Market for Academic and Research Institutes, 2022-2035 (USD Billion)
  • Figure 12.10 Biosensors in Drug Discovery Market for Industry Players, 2022-2035 (USD Billion)
  • Figure 12.11 Biosensors in Drug Discovery Market: Distribution by Region, 2022 and 2035
  • Figure 12.12 Biosensors in Drug Discovery Market in North America, 2022-2035 (USD Billion)
  • Figure 12.13 Biosensors in Drug Discovery Market in Europe, 2022-2035 (USD Billion)
  • Figure 12.14 Biosensors in Drug Discovery Market in Asia Pacific, 2022-2035 (USD Billion)
  • Figure 12.15 Biosensors in Drug Discovery Market in Latin America, 2022-2035 (USD Billion)
  • Figure 12.16 Biosensors in Drug Discovery Market in Middle East and North Africa, 2022-2035 (USD Billion)
  • Figure 12.17 Biosensors in Drug Discovery Market in Rest of the World, 2022-2035 (USD Billion)
  • Figure 13.1 Concluding Remarks: Market Landscape
  • Figure 13.2 Concluding Remarks: Funding and Investments Analysis
  • Figure 13.3 Concluding Remarks: Publication Analysis
  • Figure 13.4 Concluding Remarks: Global Event Analysis
  • Figure 13.5 Concluding Remarks: Patent Analysis
  • Figure 13.6 Concluding Remarks: Market Forecast and Opportunity Analysis